# Adjuvant Docetaxel Plus Gemcitabine in Patients With Completely Resected Leiomyosarcoma (LMS) of the Uterus

> **NCT00614835** · NA · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 25 (actual)

## Conditions studied

- Uterine Leiomyosarcoma
- Uterine Cancer

## Interventions

- **DRUG:** Docetaxel plus Gemcitabine

## Key facts

- **NCT ID:** NCT00614835
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-08
- **Primary completion:** 2006-02
- **Final completion:** 2012-01
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2015-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00614835

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00614835, "Adjuvant Docetaxel Plus Gemcitabine in Patients With Completely Resected Leiomyosarcoma (LMS) of the Uterus". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00614835. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*